AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

AstraZeneca has signed a research agreement worth more than $5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the ...

AstraZeneca has joined the long list of big pharma companies enlisting the services of Chinese biotechs, signing a deal worth ...

Friday’s deal with fits neatly within AstraZeneca’s business development strategy of upping investments in AI and in China.

CSPC will use its artificial-intelligence-driven, dual-engine efficient drug discovery platform to analyze the binding ...

The announcement builds on AZ's announcement earlier this year that it will invest $2.5 billion in an R&D facility in China, ...

The collaboration will focus on identifying pre-clinical candidates for high-priority targets, including a small molecule ...

Astra has agreed a deal that could be worth almost £4billion with a Chinese company to use AI in the production of new ...

The collaboration aims to advance the discovery and development of novel oral candidates.

Anglo-Swedish pharma major AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC ...

AstraZeneca could spend up to $5.3 billion in a deal to develop oral medicines with CSPC Pharmaceutical. Elsewhere, Insmed ...

AstraZeneca said on Friday it has agreed to a research deal with Chinese drugmaker CSPC Pharmaceuticals worth up to $5.22 ...